REDWOOD CITY, Calif., Feb. 19, 2025 /PRNewswire/ — Carbon, a leader in 3D printing technology, is excited to announce the development of FP3D, a groundbreaking flexible, removable partial denture (FRPD) resin, at LMT® Lab Day® Chicago 2025. This innovative material introduces Carbon’s…
Month: February 2025
My mom worked for Quest Diagnostics, and she always talked about what a great company it is, so I had long waited for an opportunity to also work for Quest. I actually saw three job openings for the Logistics team, and I applied for all of them to get the opportunity to work for this company. When I filled out the application, I felt the positive vibes because I knew this was my chance.
Since joining Quest, I have learned to problem solve much better. I realized there is nothing I can’t figure out. But my favorite part of the job is talking to all our clients and getting to know them. I love helping people, and Quest provides me the opportunity to do that.
We have a great team. My coworkers and I work hard to always make sure specimens are delivered promptly. When I was still kind of new, I drove out to Grover Beach to make sure that the specimens got there on time. At the time, I was terrified to drive in the snow, but I overcame my fear when my coworker and I drove out there together. I have so much respect for all of my coworkers as they make sure specimens make it to their destination. We go above and beyond for doctors and clinics, which I feel makes us stand out as a lab! We provide excellent service, and we are truly always happy to help.
I also love that Quest is good to their employees. We get a yearly bonus and raises, and we have the opportunity to grow in our roles and in the company. I also have leaders who I have learned so much from, including my Group Lead, who always guides me in the right direction, as well as a Supervisor and Regional Manager who are always supportive of me. I absolutely love and am proud to work for Quest Diagnostics.
Rare Disease Community Will Visit Over 300 Member Offices WASHINGTON, Feb. 19, 2025 /PRNewswire/ — The EveryLife Foundation for Rare Diseases (EveryLife Foundation) will welcome advocates from 49 states and Puerto Rico to Rare Disease Week on Capitol Hill, February 24 through February…
10+ new places, spaces, and recent James Beard nominations bring fresh opportunities for adventure, culinary delights, and experiences along the coast. BILOXI, Miss., Feb. 19, 2025 /PRNewswire/ — Coastal Mississippi, known for its stunning 62-miles of shorelines, vibrant culture, and…
Viral Hit “Country to the City” Sees Resurgence as Band Prepares for Album Release LOS ANGELES, Feb. 19, 2025 /PRNewswire/ — EKC PR, a premier Los Angeles-based Public Relations, Marketing, and Branding firm, is proud to welcome the viral country-rap group Good Ol’ Boyz to its growing…
This Marks the Company’s Third Time Making This Prestigious List in Four Years CALGARY, AB, Feb. 19, 2025 /PRNewswire/ – High Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value…
INDIANAPOLIS, Feb. 19, 2025 /PRNewswire/ — Premium Audio Company is proud to announce an exciting new collaboration with Marvel Television’s “Daredevil: Born Again,” delivering an unmatched audio experience as the official speakers and home audio system of the highly anticipated new…
Fighting Weedflation—One $25 Eighth at a Time HAGERSTOWN, Md., Feb. 19, 2025 /PRNewswire/ — The people have spoken and District Cannabis has answered. With the grand opening of its newest retail location in Hagerstown, MD, District Cannabis is taking on Weedflation—offering everyday low…
Existing, single-family home sales totaled 254,110 in January on a seasonally adjusted annualized rate, down 10.0 percent from 282,490 in December and down 1.9 percent from 259,160 in January 2024. January’s statewide median home price was $838,850, down 2.6 percent from December and up 6….
SAN DIEGO, Feb. 19, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of peluntamig (PT217) in combination…